Ultragenyx Pharmaceutical Inc.
NEWS
Ultragenyx Pharmaceutical Inc. announced that the Biotechnology Innovation Organization (BIO) has awarded this year’s Henri A. Termeer Biotechnology Visionary Award to Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer, President and founder of Ultragenyx.
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Monday, May 6, 2019 at 5pm ET to discuss first quarter 2019 financial results and provide a corporate update.
Two years after its acquisition of Dimension Therapeutics, Bay Area-based Ultragenyx Pharmaceutical, Inc. continues to see success in its clinical programs for the company’s adeno-associated virus (AAV) gene therapy treatments and in its overall growth.
Company on Track to Submit NDA to FDA in Mid-2019
Ultragenyx Pharmaceutical Inc. announced that management and external experts will provide an update to the investment community on the global commercial launch of Crysvita®, the company’s gene therapy programs and platform including manufacturing capabilities, and preclinical data on the next three Investigational New Drug applications the company plans to submit to the U.S. Food and Drug Administration.
First Latin American Approval of Crysvita, the only Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease
Ultragenyx Pharmaceutical Inc. today announced that it will present at the following upcoming investor conferences:
Ultragenyx Pharmaceutical Inc. announced that it has commenced an underwritten public offering of up to $250,000,000 of shares of its common stock.
JOBS
IN THE PRESS